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Abstract Newborn screening for inborn errors of metabo-
lism and endocrinopathies has expanded during the last two
decades, mainly owing to the introduction of new technol-
ogies such as tandem mass spectrometry and DNA analysis.
However, every expansion of the screening panel requires
critical review, discussion, and pilot studies. Different legal
regulations and ethical concerns may lead to different
decisions. Without claiming to be comprehensive, this review
tries to give an overview of newborn screening, including its
main problems and target diseases.
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Abbreviations
3-MCC 3-methylcrotonyl-CoA carboxylase
17-OHP 17α-hydroxyprogesterone
CAH congenital adrenal hyperplasia
CF cystic fibrosis
CH congenital hypothyroidism
CPT-I carnitine palmitoyl transferase I
DBS dried blood spots
G6P-DH glucose-6-phosphate dehydrogenase
GALT galactose-1-phosphate uridyl transferase
IRT immunoreactive trypsin
MCAD medium-chain acyl-CoA dehydrogenase
MSUD maple sirup urine disease N-acetylglutamate
synthase
PKU phenylketonuria
RIVM Dutch National Institute for Health
and the Environment
TMS tandem mass spectrometry
TSH thyroid stimulating hormone
Introduction
Screening procedures are primary tools of preventive
medicine. Their aim is to detect diseases presymptomati-
cally, or at least in early stages, in order to prevent the
outbreak or complications of the disease. A comprehensive
definition of screening was published in the first issue of the
Journal of Medical Screening [1]: “Screening is the
systematic application of a test or enquiry to identify
individuals at sufficient risk of a specific disorder to benefit
from further investigations or treatment, amongst persons
who have not sought medical attention on account of
symptoms of that disorder.” Screening programs are driven
by two different goals. One is an ethical (or Hippocratic)
goal, to spare patients the burden of the disease, and the other
is a health economic goal, to save money and resources.
In 1968 the World Health Organization published
guidelines for including diseases in screening programs,
the so-called Wilson and Jungner criteria [2]. The diseases
must be treatable, and early treatment should have advan-
tages over later treatment; therefore, the disease should have
a sufficient latency or period free of symptoms to allow early
intervention. The costs of identifying cases of the disease
must be economically justifiable. Although newborn screen-
ing should normally be uniformly applied to the whole
population, it may be justifiable to screen only a subgroup of
the newborn population for a specific disease if the incidence
Anal Bioanal Chem (2009) 393:1481–1497
DOI 10.1007/s00216-008-2505-y
R. Fingerhut : B. Olgemöller
Laboratory Becker, Olgemöller & Colleagues,
Führichstr. 70,
81671 Munich, Germany
Present address:
R. Fingerhut (*)
University Children’s Hospita-Zürich,
Swiss Newborn Screening, Steinwiesstrasse 75,
CH 8032 Zürich, Switzerland
e-mail: ralph.fingerhut@kispi.uzh.ch
in that subgroup is higher than in the rest of the population
[3]. This would increase the socioeconomic benefit without
reducing the health economic benefit. However, owing to
the high mobility of people in the modern world, establish-
ment of subgroups may be difficult or even impossible. In
addition, it should be kept inmind that theWilson and Jungner
criteria must be applied to the whole screening procedure; in
other words, a disease selection step must be as thoroughly
scrutinized as the performance of the laboratory test.
Newborn screening for inborn errors of metabolism and
endocrinopathies (performed on dried blood samples) is just
one of many screening programs. However, it is of special
importance because the benefit for the majority of detected
patients, as well as for the health care system and the
community, is enormous, especially when calculated on the
basis of total lifespan.
History of newborn screening
Newborn screening effectively started with the development
of a rational therapy for phenylketonuria (PKU) by Horst
Bickel [4, 5] in 1953, and the realization that only patients
treated early (presymptomatically) would benefit from
therapy [6]. The first PKU screening trials (the diaper test)
were based on the fact that patients with PKU excrete large
amounts of phenylpyruvic acid in the urine, which can be
visualized with Fölling’s reagent [7]. However, the sensitiv-
ity of this test for neonates was low because phenylpyruvic
acid is only excreted when phenylalanine levels in blood
exceed 900–1,200 µmol/L [8].
A breakthrough in PKU detection was provided by the
bacterial inhibition assay, invented by Robert Guthrie [9] in
1962. With that test, capillary blood, drawn by heel prick
and dried on filter paper, the so-called dried blood spots
(DBS), became the universal newborn screening specimen;
therefore, even today newborn screening is often called the
“Guthrie test”. However, it is important to note that the
basic research of Fölling [7] and Jervis [10, 11] two decades
earlier laid the groundwork for this method.
In the following years, similar tests for other metabolic
diseases such as maple syrup urine disease (MSUD) [12],
homocystinuria [13], histidinemia [14], and galactosemia
[15, 16] were developed. As screening tests became
available for more and more diseases, it became necessary
to define criteria for deciding which diseases should be
included in newborn screening programs. Fortunately, the
Wilson and Jungner criteria [2] are still valid today.
In the 1970s ELISA tests for the determination of thyroid
stimulating hormone (TSH) and thyroxine made screening
for congenital hypothyroidism (CH) possible [17, 18].
Subsequently other disorders were added to the list, such
as biotinidase deficiency [19], congenital adrenal hyperpla-
sia (CAH) [20], hemoglobinopathies [21], glucose-6-phos-
phate dehydrogenase (G6P-DH) deficiency [22], and cystic
fibrosis (CF) [23].
The introduction of tandem mass spectrometry (TMS)
[24–26] has turned the world of newborn screening upside
down, because the paradigm of “one disease–one test”
could be abandoned. Now up to 35 diseases can be detected
with one test (amino acids and acylcarnitines). Thus, there
is now hope that many diseases which were formerly
associated with poor outcomes will have a much better
prognosis because they can be detected early by newborn
screening [25, 27, 28]. Unfortunately, not all new disease
screens have been successful; for example, attempts to screen
for neuroblastoma in urine [29] did not meet expectations.
Methods for newborn screening
Newborn screening for inborn errors of metabolism and
endocrinopathies is “genetic testing,” because if the
diagnosis is confirmed clinically after a positive screening
result, the cause of the disease in nearly all cases is a genetic
defect. Therefore, genetic defects are detected regardless of
whether the screening is based on the detection of metabo-
lites (gene products) or on DNA testing [30, 31] (Fig. 1).
Newborn screening can be achieved many ways. The
most common is to screen for the biochemical phenotype at
the metabolite level, as for PKU, MSUD, organic acidurias,
and β-oxidation defects. A second approach is to screen for
the enzymatic phenotype at the protein/enzyme level, as for
biotinidase deficiency, classic galactosemia, and G6P-DH.
The third approach is to screen for the genotype at the DNA
level, as for CF. Each of the three approaches has advantages
as well as drawbacks. The screen for galactosemia can serve
as an example of these.
Galactosemia screening was initially done at the metab-
olite level. In the early days of galactosemia screening, total
galactose in DBS was estimated with a microbiological
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assay [32]. However, a reliable galactosemia test requires
patients to ingest exogenous lactose. In contrast to PKU
testing, where endogenous catabolism provides enough
material to be detected reliably in a routine screen, the
endogenous production of galactose (approximately 13–
25 mg/kg per day [33]) is not always enough to reliably
detect potential galactosemia patients. Later, quantitative
enzymatic galactose assays were used [34] for galactosemia
screening, but the problems stayed the same. Then it was
thought that the problem could be solved by the introduction
of a qualitative assay for galactose-1-phosphate uridyl
transferase activity (GALT) [15], which screens for galacto-
semia on the enzyme level. Nowadays the classical qualitative
“Beutler test” has been replaced by a semiquantitative test for
GALT [35]. This made galactosemia screening independent
of lactose ingestion. Although this increased the sensitivity
of the test, it did not improve the specificity, because the
measurement of GALT activity detects a lot of newborns
with mild enzyme variants, the so-called Duarte variants;
these patients do not need treatment [36, 37]. Furthermore,
false positives can result if enzyme activity is inactivated by
heat or disinfectants. A combination of both tests, measure-
ment of total galactose and GALT activity, can reduce both
false positives and the detection rate of Duarte variants.
Further improvement requires a two-tier strategy to identify
carriers of the Duarte mutations [38], and thereby exclude
classic galactosemia.
Two-tier strategies, which use DNA testing as the second
step, can also help to significantly reduce the recall rate in
other screening tests that suffer low specificity on the
metabolite level, such as CF screening [39] and CAH
screening [40]. However, in many countries, whenever
DNA testing is performed, legislation mandates informed
consent (from either patient or parent) and genetic
counseling (if the result is positive). This causes extra
expense for the screening organization and may hamper
screening workflow.
Newborn screening tests that rely solely on DNA testing
are rare and can only be applied to diseases and populations
that have a major mutation with a very high frequency such
as the ΔF508 mutation in CF patients of northern European
descent [41]. Therefore, nearly all screens for CF still use
the two-tier strategy.
Alternative strategies have been proposed to avoid DNA
testing. Early screening programs for CF [42] required a
second sample at the age of 6 weeks for immunoreactive
trypsin (IRT) if the IRT level was elevated in the first
sample. More recently, a combination of IRT and pancreas-
associated protein determinations has been described; initial
trials have been conducted on this approach [43–45].
Testing can be further improved by using three-tier
protocols. The CF screening workflow in the UK combines
an IRT/DNA testing strategy for the first sample, then tests
a second sample for IRT if the first result does not exclude
CF. This protocol results in very low rates of confirmatory
sweat tests and unwanted carrier detection.
All methods suitable for newborn screening must have
some major features in common: They must support a high
throughput, they should be sensitive and specific, and they
must be inexpensive. In most countries newborn screening
is centralized in regional screening laboratories. In many
countries a minimum number of screening samples is
recommended, in order to provide testing agencies with
sufficient expertise to detect even very rare disorders. In
Germany, for example, a minimum of 50,000 newborn
screening samples per year is mandatory.
Radioimmunoassay, ELISA, or fluoroimmunoassay tests
are available for TSH (CH screening), 17α-hydroxyproges-
terone (17-OHP; CAH screening), and IRT (CF screening).
The use of the AutoDelfia™ kits is widespread. These kits
use time-resolved immunofluorescence with europium(III)-
labeled antibodies. The AutoDelfia tests are approximately
10 times more sensitive than comparable ELISA tests with,
for example, β-galactosidase-coupled antibodies [46].
The tests for galactosemia, biotinidase deficiency, and
tyrosinemia type I (inhibition of the porphobilinogen synthase
by succinyl acetone) are photometric or fluorimetric enzyme
assays.
Hemoglobinopathies are detected by isoelectric focusing
of the hemoglobin chains. This is a labor-intensive test, and
large screening laboratories must have many isoelectric
focusing apparatuses.
Amino acidemias, organic acidurias, β-oxidation disor-
ders, and carnitine cycle disorders are detected with TMS.
The TMS technique has long been known; it was first
described by Thomson [47] in 1909. However, this method
only became suitable for high-throughput screening with the
advent of multiquadrupole technology, which was intro-
duced by Yost and Enke [48], and electrospray ionization,
which was described by Dole et al. [49] and introduced by
Yamashita and Fenn [50, 51] in 1984.
The TMS technique will be discussed in detail elsewhere
[52]. Briefly, for newborn screening, normally triple-
quadrupole mass spectrometers are used. In the first
quadrupole, selected ions are filtered according to their m/z
ratio (molecular mass to charge). After collision-induced
dissociation in the collision cell (quadrupole 2), specific
fragments can be analyzed in the third quadrupole. Amino
acids and acylcarnitines are extracted from the DBS with
methanol. These can be analyzed either directly or after they
have been converted to their butyl esters. Both methods have
advantages and disadvantages. Direct analysis is faster, but
the butylation method is more sensitive (mean limit of
detection/limit of quantitation 0.08/0.13 µmol/l for butylated
acylcarnitines, and 0.20/0.30 µmol/l for underivatized
acylcarnitines, respectively). For underivatized metabolites,
Newborn screening for inborn errors of metabolism and endocrinopathies 1483
analysis requires choosing a specific pair of ions, one from
the first quadrupole and one from the third quadrupole. For
the butylated amino acid a neutral loss of 102 is character-
istic; for the butylated acylcarnitines, a product ion ofm/z=85
is characteristic.
Age at sampling for newborn screening
Most screening programs are based on a single sample
taken at a certain recommended age. There are only a few
programs, for example, in Texas [53], that test a second
sample from all newborns.
Unfortunately, different diagnostic indicators appear at
different ages. Enzyme activities (e.g., biotinidase, GALT,
G6P-DH) are not influenced by the age of the child.
However, many metabolite levels are age-dependent. For
example, TSH and especially 17-OHP levels increase
during delivery, but normalize quickly within the first
24 h. Other metabolites, such as amino acids that are
transported across the placenta, will increase with time in
affected patients. The velocity of this increase depends on
the magnitude of the enzyme defect. Acylcarnitines do not
seem to be transported across the placenta; therefore, their
levels are already elevated at birth.
Thus, the age at which blood is collected for newborn
screening is always a compromise. In general, it is desirable
to detect patients as early as possible to allow sufficient
time for intervention prior to the onset of symptoms. For
example, early screening is crucial for disorders such as
MSUD, propionic acidemia, and methylmalonic acidemia,
in which symptoms appear during the second week of life.
If screening is not early enough, patients may suffer life-
threatening metabolic decompensation. On the other hand,
early screening may decrease sensitivity and specificity.
Blood collection during the first 24 h of life would result
in high recall rates for CH and CAH. PKU andMSUD can be
detected after approximately 8 h of life, while methionine in
homocystinuria might only be increased after the fifth day of
life. Organic acidemias can be detected from birth, and fatty
acid oxidation defects are best detected when the babies are
maximally catabolic. So what is the optimal time point for
blood collection for newborn screening?
In Germany the recommended time for blood sampling is
between 36 and 72 h of life. This guideline takes the above-
mentioned arguments into account. However, another impor-
tant factor in determining sampling time is that the majority of
mothers will leave the hospital during that 36–72-h time
frame. Thus, that time frame was chosen to ensure sampling at
the place of birth, which is desirable in order not to lose track
of patients. In summary, the standard practices of health-care
facilities will also influence the choice of sampling age; these
practices may be different in different countries.
Target diseases
An overview of the diseases listed below is given in Table 1.
Target diseases differ with respect to their relevance ranking
and their inclusion in screening programs.
High relevance ranking, included in most programs
Endocrinopathies
Congenital hypothyroidism
The worldwide incidence of primary CH is approximately
1:4,000. The majority of cases are due to sporadic dysplasia
of the thyroid. Only 10–20% of the cases are due to
genetically determined deficiencies of peroxidase or deio-
dinase. The first clinical signs of CH are rather nonspecific,
such as prolonged icterus and failure to thrive. Early
detection (by newborn screening) and treatment will lead
to normal development of patients with primary CH;
delayed treatment will result in psychomotor and mental
retardation. The screening method of choice is determina-
tion of TSH. Secondary CH (TSH deficiency) will not be
detected by TSH screening. However, the incidence of TSH
deficiency is low (1:40,000–1:90,000), and those patients
who were detected owing to their short stature did not
showed mental retardation [150].
Congenital adrenal hyperplasia
CAH can be caused by several enzyme deficiencies
(steroid-21-hydroxylase, 11β-hydroxylase, 3β-hydroxyste-
roid dehydrogenase, 17α-hydroxylase, 20-lyase, and cho-
lesterol desmolase). Deficiency of steroid-21-hydroxylase is
the most frequent and clinically most important cause
[151]. The worldwide incidence is approximately 1:14,000
[152]. The condition has a broad spectrum of clinical
presentation, ranging from salt wasting through simple
virilizing to nonclassic forms. Screening programs that use
a single sample taken shortly after birth may only be
sensitive enough to detect the salt-wasting forms. About
61% of simple virilizing and 87% of nonclassic forms can
only be detected through a second screen at around 1–
2 weeks of age [53, 113]. CAH screening also has
additional problems. 17-OHP levels are highly variable
owing to neonatal stress and the cross-reactivity of widely
used ELISA tests with steroid sulfates. This variability
increases the rate of false positives, especially in premature
and critically ill infants. Many published studies have tried
to avoid unnecessary controls by adjusting cut-off levels to
gestational age [153], birth weight [154], birth weight and
age [155]. Other approaches have involved introducing a
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second-tier test, either with TMS [156, 157] or molecular
genetic analysis [40].
Amino acidopathies
PKU and MSUD
Classic PKU results from a defect of phenylalanine hydrox-
ylase. Phenylalanine hydroxylase converts phenylalanine to
tyrosine, with tetrahydrobiopterin as a cofactor. In untreated
patients, phenylalanine accumulates and is converted to toxic
phenylpyruvate. During the first months of life, PKU patients
seem to develop normally. The first clinical signs are vomiting,
failure to thrive, and, later, severe mental retardation, epilepsy,
dysmyelination (or demyelination) in the brain, and a mousy
odor of the urine (due to the excretion of phenylpyruvic acid).
The incidence of PKU is 1:11,000. Hyperphenylalaninemia,
characterized by phenylalanine hydroxylase activities of about
3–10%, does not require treatment (incidence 1:10,000).
Atypical PKU, due to a defect in tetrahydrobiopterin
metabolism, is generally very rare; however, the incidence is
higher in East Asia [158].
MSUD is caused by a defect of the branched-chain oxo
acid dehydrogenase complex. Reports on the total incidence
have arrived at quite different numbers. Apart from special
populations such as the Mennonites from Pennsylvania
with an incidence of 1:358 [159], the overall incidence was
estimated to be around 1:245,000 in the USA [12]. Collab-
orative data from Europe reported a total incidence of about
1:120,000 [160], and results from the Bavarian screening
program from 1999 to 2008 (1:115,000) support these data.
Since amino acids are transported through the placenta,
levels of phenylalanine and branched-chain amino acids are
normal at birth in neonates with PKU and MSUD, respec-
tively. Concentrations in blood rise postpartum. In individual
cases of PKU, increased phenylalanine levels were reported
just 6 h after birth [161]. Elevations of the levels of branched-
chain amino acids have been observed in MSUD 24 h after
birth [162, 163]. Glucose infusion during the first day of life
without enteric nutrition may prevent protein breakdown and
is a possible cause of false-negative screening results [164].
Early intervention in MSUD is crucial to avoid severe
metabolic decompensation, which may lead to coma (or
death) or may require extracorporal detoxification [61].
Organic acidurias
Glutaric aciduria type I
Glutaric aciduria type I (glutaryl-CoA dehydrogenase
deficiency) is a defect of leucine catabolism. The overall
incidence of glutaric aciduria type I is around 1:85,000
[165]. Untreated patients show normal development during
the first weeks or months of life. The first manifestations,
often triggered by febrile illness, are dystonia and extrapy-
ramidal movement disorders. Early detection of patients by
newborn screening, followed by prevention of the encepha-
lopatic crisis, are a promising approach to ensuring normal
development. Newborn screening for glutaric aciduria type I
bears the risk of false-negative results when the first
screening sample is taken rather late (after the seventh day
of life) or when only a second DBS for acylcarnitines is taken
after a positive screening result [166]. Extensive guidelines
for diagnosis and management have been published [167].
They recommend the analysis of organic acids in urine as a
confirmatory test. However, in some low excreters or
nonexcreters, this confirmatory test might give a normal
result, and hence a false-negative result is possible [168, 169].
In our experience, administering an additional “diagnostic”
carnitine load over 2 days improves screening sensitivity.
After the carnitine load, glutaryl carnitine levels in affected
patients are increased around sevenfold to eightfold.
Isovaleric acidemia
Isovaleric acidemia (isovaleryl-CoA dehydrogenase deficien-
cy) is a defect in the catabolic pathway of leucine; the
incidence is 1:75,000. Patients with the acute form of
isovaleric acidemia present clinically within the first days of
life with poor feeding, vomiting, and lethargy. Patients with
the chronic intermittent form develop similar symptoms, but
the age of onset is later. The marker metabolite in DBS is
isovaleryl carnitine. Newborn screening for isovaleric acid-
emia has also detected milder variants, which will probably
stay symptom-free without any treatment [170]. In addition,
TMS cannot distinguish isovaleryl carnitine from 2-methyl-
butyryl carnitine, which means the screen also detects 2-
methyl butyryl-CoA dehydrogenase deficiency, presumably
a benign condition [171, 172].
β-Oxidation and carnitine cycle defects
Medium-chain acyl-CoA dehydrogenase deficiency
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency
is the most prevalent of the β-oxidation and carnitine cycle
disorders, with an incidence of 1:10,000. The first clinical
manifestation is vomiting and lethargy, progressing to coma
and death if left untreated. These periods are normally
preceded by viral infection in the gastrointestinal or upper
respiratory tract. The mortality rate in undiagnosed MCAD
cases is 20–25% [173].
Fasting hypoglycemia with low or absent ketone bodies is
the leading symptom for all disorders affecting the mitochon-
drial β-oxidation pathway. Early diagnosis unquestionably
improves the prognosis for MCAD deficiency, although
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newborn screening also detects (biochemically) affected
newborns (mild variants with MCAD activities of 10–20%
of normal [174]) that might never develop clinical symptoms.
Other β-oxidation and carnitine cycle defects
For the defects affecting the β-oxidation of long-chain fatty
acid, namely, deficiencies in carnitine acylcarnitine trans-
locase and carnitine palmitoyl transferase II, the prognosis,
even after early detection, is not so promising. For the very
long chain acyl-CoA dehydrogenase and long-chain
hydroxyacyl-CoA dehydrogenase deficiencies, there seem
to be different forms that show either neonatal (severe
forms) or later onset (milder forms). However, owing to the
low incidence of these disorders, there are currently too few
data available to reach a final decision about including
these disorders in screening programs.
However, for the carnitine palmitoyl transferase I (CPT-I)
and multiple acyl-CoA dehydrogenase deficiencies, the situa-
tion is different. Newborn screening for CPT-I deficiency is
highly sensitive and specific, and a rational therapy is available
[108]. For multiple acyl-CoA dehydrogenase deficiency a
promising therapeutic approach with butyrate supplementation
(e.g., ketone bodies as an energy source) is available [175].
All β-oxidation and carnitine cycle disorders produce
specific acylcarnitine profiles in TMS analysis.
Other disorders
Biotinidase deficiency
Biotinidase is an enzyme that releases biotin from biocytin,
which is formed by proteolytic degradation of biotin-
containing carboxylases. Two forms of biotinidase deficiency
are known, profound and partial biotinidase deficiency, with
less than 10% and 10–30% residual activity, respectively. The
overall incidence is around 1:120,000. Clinical signs may
develop as early as the first week of life or up to 10 years of
age. Mainly the central nervous system and the skin are
affected [176]. Late-diagnosed patients often develop psy-
chomotor retardation, hearing loss, optic atrophy, skin
lesions, and hair loss, which may be irreversible. Therapy
consists of biotin substitution. The enzyme activity is
measured photometrically or fluorimetrically in newborn
screening.
Galactosemia
Three different forms of galactosemia are known: GALT
deficiency, with an incidence of 1:72,000, galactokinase
deficiency, with an incidence of 1:250,000, and the very rare
galactose-4′-epimerase deficiency [177]. GALT deficiency
(classic galactosemia) will lead to life-threatening illness
within the first weeks of life, with vomiting, jaundice,
hepatomegaly, lethargy, hypotonia, and disturbance of
blood clotting. Patients with galactokinase deficiency mainly
present with bilateral cataracts. Galactose-4′-epimerase
deficiency can be expressed either solely in red blood cells,
which causes no symptoms, or in all cells and organs, which
leads to developmental delay, hypotonia, and poor growth.
For galactosemia screening two tests are widely used,
metabolite assay (galactose plus galactose-1-phosphate)
and measurement of GALT activity. The metabolite assay
can identify all three forms of galactosemia, but ingestion of
galactose/lactose is necessary to ensure detection of positive
patients. The GALT test does not require galactose/lactose
uptake, but it can detect only classic galactosemia. False-
positive results can be caused by secondary inactivation of
enzyme activity (by heat, etc.). Different screening strategies
may be used: (1) initial measurement of total galactose, with
measurement of GALT activity only in cases where early
blood sampling shows elevated levels of galactose; (2) initial
measurement of GALT activity and therefore restriction of
screening to classic galactosaemia; and (3) measurement of
both total galactose and GALT activity in all samples.
The third strategy has major advantages, yet costs only a
little more. In cases of classic galactosemia, the tentative
diagnosis is verified by two different methods within 2–4 h
after sample receipt. Secondly, Duarte variants and Duarte/
classic galactosemia compound heterozygotes, which do
not need treatment, are identified at a much lower rate.
Cystic fibrosis
CF is the most frequent metabolic disorder in the northern
hemisphere. It is caused by mutations in the CF transmem-
brane conductance regulator gene. The gene product is a
glycoprotein that regulates ion flux at epithelial surfaces. A
defective CF transmembrane conductance regulator protein
causes thick secretions that obstruct pancreatic ductules and
lead to pancreatic insufficiency; further, the dehydration of
airway surfaces leads to chronic obstructive pulmonary
disease. The incidence in the Caucasian population is
approximately 1:3,500. Global introduction of CF screening
in the past was hampered by conflicting opinions on whether
newborn screening could positively effect prognosis. How-
ever, recent studies have clearly shown the clinical, social, and
economic benefit [126, 127, 178]. The initial screening
parameter is IRT, measured by fluoroimmunoassay or
ELISA. However, measurement of IRT has a high false-
positive rate. There are different strategies for reducing
false-positive results [41]. The most promising seems to be a
combination of the South Australian [179] and the UK
strategy [180]. Briefly, IRT is measured in all DBS. In
samples with results above the 99th percentile, DNA
analysis is done. If no mutation is found and the IRT level
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is below the 99.9th percentile, there is no suspicion of CF. If
the IRT level is above the 99.9th percentile (fail-safe step), or
one mutation is detected, a second sample is requested. Only
those newborns who either have two detectable mutations or
still show elevated IRT levels in the second sample need to
be referred to a specialized center for a sweat test. With this
protocol the number of sweat tests required is extremely low
(approximately 0.01%), and the rate of second testing (IRT)
is approximately 0.13%.
The problem of false-negative IRT results, especially in
meconium ileus, is not affected by this approach; therefore,
the rate of false-negative screening results will be less than
0.001% (approximately one missed CF case in 150,000
screened newborns) [181, 182]. However, despite the
considerable advantages of two-tier strategies, even existing
programs are stepping back from DNA testing.
Reasonable in selected populations
G6P-DH deficiency
G6P-DH deficiency is the most common enzyme defect in
humans. The global distribution resembles that of malaria,
with the highest frequencies in tropical Africa and tropical
and subtropical Asia. G6P-DH deficiency is an X-linked
genetic defect that causes a variety of clinical symptoms,
such as neonatal jaundice and acute hemolytic anemia,
triggered by exogenous agents and oxidative stress (for a
review see [120]).
Hemoglobinopathies
The incidence of hemoglobinopathies is higher in populations
with African or Mediterranean decent [183]; therefore, many
screening programs will only screen selected populations.
However, in the future, high mobility and migration typical
of modern communities will alter the situation. Recommen-
dations in Belgium and the UK already support nonselective
screening [114, 116].
Questionable owing to major problems
Amino acidopathies
Tyrosinemia type I and homocystinuria
Untreated tyrosinemia type I leads to liver failure during the
first weeks or months of life. Homocystinuria affects the
eye, skeleton, and nervous tissue, and leads to dislocation
of the lens, osteoporosis, mental retardation, and thrombo-
embolic complications that often cause stroke in the second
or the third decade of life. Early treatment is desirable for
both conditions [65]. Succinylacetone and homocysteine
are the metabolites which primarily accumulate as a result
of the enzyme defect. Unfortunately these are not easily
quantifiable in routine TMS screening programs. Tyrosine
and methionine, which may accumulate later, serve as
secondary markers. Therefore, sensitivity is low. Because of
nonspecific elevations of tyrosine levels in transient tyrosi-
nemia, and methionine in hepatopathies or in babies on
hypoallergenic alimentation, test specificity is also limited.
Attempts have been made to introduce succinyl acetone and
homocysteine in routine screening [68, 69, 184, 185].
However, these require either preparation of separate
samples (succinyl acetone) or extra analytical procedures
(homocysteine) and do not ideally meet economic screening
criteria. A novel strategy for tyrosinemia screening involves
extracting the same DBS twice and derivatizing the samples
differently, then combining the derivatives and performing
only a single measurement [66].
β-Oxidation and carnitine cycle defects
Carnitine transporter defect (OCTN2)
The carnitine transporter transfers carnitine from the
extracellular matrix into the cytosol. Because renal tubular
cells are unable to reabsorb carnitine, patients lose most of
their ingested carnitine through the kidneys; therefore,
plasma carnitine levels of most patients are extremely low.
This may result in hypoglycemia, hepatic encephalopathy,
cardiomyopathy, and even sudden death [107]. Newborn
screening for carnitine transporter deficiency is hampered
by two facts. First, the levels of free carnitine in the
newborn period are strongly dependant on and influenced
by maternal free carnitine levels; therefore, the free
carnitine level can be normal in patients with carnitine
transporter deficiency (because of high maternal levels),
leading to false-negative screening results. It can also be
low in normal children (because of low maternal levels),
leading to false positives. Second, decreased levels of free
carnitine can lead to diagnosis of a carnitine transporter
deficiency in the (asymptomatic) mother. Despite being
asymptomatic in adulthood, some of the mothers, detected
through newborn screening of their child, had one or more
episodes of metabolic decompensation in early childhood,
requiring hospitalization; no definite diagnosis was made at
that time. While it is reasonable to detect affected
newborns, since metabolic decompensation may be pre-
vented by simple carnitine substitution, it is problematic to
detect asymptomatic mothers, because nothing is known
about the risk of metabolic decompensation in adulthood.
This leads to the ethical problem of whether or not to treat
an adult who is, so far, clinically healthy.
1490 R. Fingerhut, B. Olgemöller
Organic acidurias
Propionic acidemia, methylmalonic acidemia,
and disorders of cobalamin metabolism
Propionic acidemia, methylmalonic acidemia, and disorders
of cobalamin metabolism (except types E and G) all have
the same marker metabolite, propionylcarnitine. For the
severe forms, clinical symptoms (vomiting, failure to thrive),
biochemical findings (ketoacidosis, hyperammonemia), and
the initial therapeutic approach are also quite similar (for
reviews see [186, 187]). The different disorders cannot be
discriminated through DBS acylcarnitine profiles. Howev-
er, inclusion of a DBS homocysteine determination could
improve both specificity and sensitivity for disorders of
cobalamin metabolism. So far, there is no evidence that
patients detected by newborn screening have a more
favorable outcome than patients detected clinically [90].
3-Methylcrotonyl-CoA carboxylase deficiency
3-Methylcrotonyl-CoA carboxylase (3-MCC) deficiency
was formerly thought to be a very rare organic aciduria.
Patients usually present with vomiting, opisthotonos,
seizures, and coma. With the introduction of TMS-based
newborn screening, it turned out that elevations of the
marker metabolite (hydroxyisovaleryl carnitine) was the
most common anomaly seen in the acylcarnitine profile
[188]. However, very few children with abnormal biochem-
istry develop symptoms typical of 3-MCC deficiency. In
addition, a great number of biochemically affected, but
clinically normal mothers were detected owing to elevated
hydroxyisovaleryl carnitine levels in newborn screening
samples of their children [189]. The results of the Munich
study [95] and a second study from Switzerland [190]
strongly suggest that newborn screening for 3-MCC defi-
ciency causes more harm (stigmatization, anxiety, decreased
quality of life) than good; therefore, newborn screening for
3-MCC deficiency was discontinued in Germany.
Nevertheless, a consensus clinical practice protocol for
the diagnosis and management of 3-MCC deficiency has
been published [191].
3-Hydroxymethylglutaryl-CoA lyase deficiency,
3-methylcrotonylglycinuria, holocarboxylase synthase
deficiency, and β-ketothiolase deficiency
These disorders have the same primary marker metabolite
as 3-MCC deficiency, 3-hydroxyisovaleryl carnitine; how-
ever, the concentrations are 10–20-fold lower than in severe
3-MCC deficiency. Although they are very rare, all of these
diseases could benefit from early treatment. However,
inclusion of these disorders in a screening program is only
possible at the cost of a high recall rate and the fact that the
nondisease 3-MCC deficiency is codetected.
Urea cycle disorders
Newborns with neonatal onset of urea cycle disorders, e.g.,
severe forms of citrullinemia, usually become symptomatic
during the first days of life. In most cases diagnosis
precedes the screening result; therefore, screening appears
to be unnecessary.
Beyond that, screening for urea cycle disorders is
problematic for several other reasons. Some of the disorders,
such as deficiencies of N-acetylglutamate synthase, carba-
moylphosphate synthase, and ornithine transcarbamylase,
are not detected by TMS screening in early life because of
normal amino acid profiles. Furthermore, quantitation of the
basic amino acids citrulline, argininosuccinic acid, and
arginine is analytically more problematic than that of other
amino acids that may cause false positives. Finally, screening
for citrullinemia yields a high proportion of children with
mild enzyme defects, but without clinical symptoms [192].
Arginase deficiency seems to be the only urea cycle
disorder suitable for newborn screening, because the onset
of clinical symptoms is later than in other urea cycle defects
and early treatment improves prognosis [73, 74].
Value of newborn screening not yet settled
Malonyl-CoA decarboxylase deficiency and disorders
of creatine metabolism
The feasibility of newborn screening for these disorders has
been demonstrated [94, 123, 193]. Patients clearly benefit
from treatment, which prevents cardiac decompensation in
malonyl-CoA decarboxylase deficiency and can prevent severe
developmental delay. Creatine supplementation in patients
with disorders of creatine metabolism improves extrapyramidal
movement disorders [194]. However, so far no results from
prospective studies or pilot projects are available.
Discontinued
Histidinemia
Histidinemia is a common disorder of amino acid metab-
olism with an incidence similar to that of PKU. The
underlying defect is a deficiency in histidase [77]. Because
some patients with developmental deficits exhibited high
histidine levels [78–80], a causal relationship was sus-
pected. However, a prospective study conducted over a
28-year period in Manchester with 104 patients clearly
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showed that histidinemia is a benign metabolic condition
that does not require treatment [81].
Hydroxyprolinemia
Hydroxy-l-proline oxidase deficiency is a rare autosomal
recessive disorder of hydroxyproline catabolism. Formerly
hydroxyproline was detected by screening programs that
used thin-layer chromatography for PKU screening. With
the introduction of TMS to newborn screening, hydroxpro-
line is detected together with the isobaric amino acids
leucine, isoleucine, and alloisoleucine.
Despite the fact that, for decades, hydroxyprolinemia has
been regarded as a harmless biochemical abnormality [82,
83], recently two new “patients” have been reported; these
were detected by TMS newborn screening [84, 195]. Clearly,
such elevated hydroxyproline levels should not be reported.
Neuroblastoma
Neuroblastoma, a malignant tumor of embryonal cells in
the neural crest, is a rare childhood cancer. From 1:7,000 to
1:10,000 liveborn children develop clinically relevant
neuroblastoma before the age of 15. The incidence in the
first year of life is about 30 per million and drops to less
than one per million at the age of 15 years. The tumors
secrete catecholamine and dopamine; abnormal levels of
their metabolites, vanillylmandelic acid and especially
homovanillic acid, are excreted in the urine. The tumors
are categorized into six stages (I, IIA, IIB, III, IV, and IVS),
with increasing severity and decreasing survival rate at
diagnosis for stages I–IV. The survival rate for stage I is
nearly 100%, but is less than 20% for stage IV. Screening
programs for neuroblastoma used filter paper soaked with
urine taken at the age of 6 months. This type of sample
collection made posting to centralized laboratories quite
easy. However, studies in North America and Germany
showed that there is no clear evidence for a positive effect of
screening, i.e., a reduction of death rate due to neuroblastoma.
Rather, screening showed a negative effect in the sense that
tumors (especially of stages I and IVS) were obviously
overdiagnosed, because quite a few of those tumors showed
spontaneous regression without therapy (for a review see
[141]). Despite these negative results [142], a new screening
approach has recently been proposed in Japan [196].
Further problems and concerns
DNA Testing
Although genetic testing can also be accomplished on the
metabolite or protein level (Fig. 1), the term “genetic
testing” in the strictest sense applies only to techniques which
analyze DNA and RNA. Genetic tests are used as a health-
care tool to detect gene variants associated with a specific
disease or condition; they are also used in nonclinical
applications such as paternity testing and forensics. They
can confirm a suspected diagnosis and also predict the
possibility of future illness. The recent development of chip
technologies and multiparameter tests makes it likely that
genetic tests will increasingly be used in diagnostic applica-
tions. Mutations causing illness will be detected with simple
and cost-effective tests. Economic arguments therefore will
not stop the introduction of these technologies.
DNA tests can also supplement newborn screening.
They can be especially helpful as second-tier tests that
confirm or exclude a disease when the primary test for a
protein or metabolite level is positive; CF testing is the
classic example.
Of course, they can also be used for primary screening;
however, screening agencies will have to address several
issues if they are using DNA testing as a primary screen:
& Carrier detection. As well as detecting children that
may be at risk, DNA tests simultaneously reveal that
unaffected individuals (the parents) are carriers. Knowl-
edge that they are carriers may be important to these
parents for future family planning. Therefore, genetic
counseling is mandatory when DNA tests are used. If an
entire population is screened, it may be difficult to keep
this claim of adequate information alive.
& Fear of genetic testing. Since people have become
concerned about the possible misuse of genetic infor-
mation, especially in health insurance and employment,
these public fears of genetic discrimination may hinder
scientific advances in newborn screening [197]. To be
successful, a population screening requires a high
participation rate, i.e., all newborns must be examined.
Since informed consent is mandatory, successful new-
born screening requires the parents’ acceptance [198].
Unfortunately, the general public is frequently unable to
discriminate between the directed search for or exclu-
sion of a specific disease and an undirected multipa-
rameter exploration of the whole genome. Therefore,
the inclusion of DNA tests in newborn screening may
lower participation. When new technologies are being
introduced, every effort must be made to keep public
information and the resulting participation rate high.
The burden of nondisease
‘“Non-disease” is a medical problem that some have
defined as a medical problem but where people may have
better outcomes if the problem was not defined in that way’
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[199]. With respect to newborn screening, nondisease may
be defined as a biochemical condition, differing from
normal, which may never cause a disease (in the narrow
sense that disease equals developing symptoms). However,
when confronted with such a diagnosis, the child, its family,
and the public health system must currently shoulder a
considerable burden.
Most target diseases of newborn screening are caused by
enzyme deficiencies that result in biochemical abnormalities.
If the deficiency is only partial, residual enzyme activity may
be sufficient for maintaining proper physiologic function.
Thus, the child will test positive, but will never suffer from
the corresponding disease.
Although the spectrum of diseases that can be detected
analytically has increased during the last decade, especially
after the introduction of TMS, the detection of nondisease
is not a new issue. For instance, during a screen for PKU,
the nondisease hyperphenylalaninemia, which does not
require treatment, is also detected because the marker
metabolites are the same for both. However, in this case
there is agreement on the approaches used for confirmation
and treatment. Cut-off levels and decision thresholds for the
start of treatment are well defined and internationally
consistent.
Problems associated with nondisease have even arisen in
screens for MCAD deficiency. The positive effect of
screening is unquestioned, and a considerable reduction in
mortality and morbidity is well documented [200]. How-
ever, patients detected by newborn screening show a
different mutational pattern from those detected clinically.
The common mutation c.935A>G (Lys329Glu) is less
common in the newborn screening population than in the
population detected via clinical symptoms. Moreover, a
mild folding variant c.199T>C (Tyr67His), so far not
reported in clinically symptomatic patients, is quite frequent
in patients detected by newborn screening [102, 201]. The
spectrum of clinical severity in MCAD-deficient patients
seems to range from severe neonatal onset to mild variants
that may never become symptomatic. Unfortunately there
seems to be no good way to predict risk.
For those diseases which have a poorly defined history,
additional problems remain. Two typical examples are 3-
MCC deficiency and carnitine transporter deficiency.
3-MCC deficiency was part of the Bavarian pilot project
to evaluate expansion of newborn screening. This pilot
project [95] produced a result for 3-MCC deficiency that
was consistent with the result from a Swiss study [190].
These two studies investigated a total of 47 patients whose
(biochemical) 3-MCC deficiency was detected by newborn
screening, and an additional four siblings and nine mothers
who were detected through family investigations. On the
basis of the results of the newborn screening in Bavaria and
published cases of clinically diagnosed 3-MCC deficiency,
a cautious calculation was made to estimate the risk that
patients with biochemical 3-MCC deficiency would devel-
op symptoms. The risk of death was estimated to be
approximately 1:8,500,000, and the risk of developing
clinical symptoms was estimated to be approximately
1:1,200,000. This means that far less than 10% of
biochemically affected individuals might develop minor
clinical symptoms, and less than 1–2% might have a risk of
severe outcome. In addition, both groups did not show a
clear correlation between genotype and phenotype, suggest-
ing that other factors in addition to the genotype at the
3-MCC loci might have a major influence on the phenotype
of 3-MCC deficiency.
For carnitine transporter deficiency the situation was quite
similar [97, 107, 202]; however, the clinical expressivity
and penetrance, or susceptibility to metabolic decompensa-
tion (at least in childhood) might be higher than in 3-MCC
deficiency.
Those who make decisions about newborn screening
panels need to carefully balance the positive and negative
effects of screening for a certain condition. At the screening
stage, the choice to include or exclude a condition still
exists. Once a patient has been identified, it can be quite
problematic to decide not to treat that individual (who is
healthy so far) in the absence of scientific evidence that a
certain condition does not cause disease. Gaining such
evidence might take decades and lead to dozens of
unnecessarily treated individuals, as we have learned from
our experience with histidinemia [203].
Maintaining process quality in newborn screening
Newborn screening is a complex process, with many people
and institutions involved. Midwives, nurses, obstetricians,
and pediatricians at the maternity clinic are the first link of
the chain. The mail delivery service, the screening
laboratory, local pediatricians, and metabolism or endocri-
nology centers are the other links. In this context, screening
failure cannot be solely defined as a laboratory error.
Rather, screening failure means a child with a disease that is
included in the screening program is not treated for this
disorder until it develops clinical symptoms. The reasons
for failure can be manifold and can occur at all stages of
newborn screening: For example, failure could be due to
forgotten specimen collection, mix-up of newborns, samples
lost during delivery, laboratory errors, errors in communi-
cating a positive screening result, follow-up specimen not
received, etc.
“Fail-safe” mechanisms were defined more than 20 years
ago [204]. Quality control schemes that check the perfor-
mance of the screening laboratories are available world-
wide. However, mechanisms to check the integrity of the
whole process are rather rare.
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Nonetheless, it is still possible to check the integrity of
the screening process, as will be shown by two examples.
In the Netherlands newborn screening is operated under the
supervision of Dutch National Institute for Health and the
Environment (RIVM). Every newborn must be registered at
the local town hall immediately after birth. After registration
the regional vaccination authority is informed and every child
is given a specific screening number. After 72 h blood for
newborn screening is drawn by a health-center assistant or an
obstetrics assistant. Tracking of positive screening results is
also supervised by the RIVM. In Bavaria (Germany) the
public health screening center is in charge of ensuring that
every newborn is screened. After informed consent has been
obtained, the screening center will receive notification from
the screening laboratory that a certain child has been
screened. The screening center now distributes the notifica-
tions to the corresponding local health authorities, where the
newborns must be registered. The local health authorities
check that every child in their field of responsibility is
screened. The public health screening center is also respon-
sible for tracking of positive screening results [199, 205].
Other screening programs may have different ways to
check the integrity of the screening process. Other reasons
for false-negative screening results, such as exchange
transfusion, dopamine or corticosteroid therapy, and high-
dose glucose infusion during the first days of life, are well
known. Therefore, continuous education of the many
(frequently changing) people involved in blood collection
is crucial so that the procedures for drawing a second
screening sample at the right time are well established.
Challenge of further extension
Every effort should be made to keep the success and
positive reputation of newborn screening high. This
requires continuously working on and, if possible, improv-
ing the sensitivity and specificity of newborn screening.
Newborn screening programs should base further extension
on established scientific knowledge. However, inclusion
criteria for target diseases must also be strictly taken into
account. Decision-makers must consider the benefit to the
individual patients and their families, to the community,
and to the health-care system.
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